Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer

British Journal of Cancer

Volumn 107, Issue 1, 2012, Pages 137-142

  Einama, T ^a,b   Homma, S ^a   Kamachi, H ^a   Kawamata, F ^a   Takahashi, K ^c   Takahashi, N ^a   Taniguchi, M ^b   Kamiyama, T ^a   Furukawa, H ^b   Matsuno, Y ^d   Tanaka, S ^c   Nishihara, H ^a   Taketomi, A ^a   Todo, S ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b ASAHIKAWA MEDICAL COLLEGE   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

^d HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

Author keywords

gastric cancer; luminal membrane expression; Mesothelin

Indexed keywords

MESOTHELIN;

ADULT; ARTICLE; CANCER SURVIVAL; CELL MEMBRANE; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; OVERALL SURVIVAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RELIABILITY; STOMACH CANCER;

AGED; EPITHELIAL CELLS; FEMALE; GPI-LINKED PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84863006209     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.235     Document Type: Article

References (26)

1. Argani P, Iacobuzio-Donahue C, Ryu B, Rosty C, Goggins M, Wilentz RE, Murugesan SR, Leach SD, Jaffee E, Yeo CJ, Cameron JL, Kern SE, Hruban RH (2001) Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 7: 3862-3868 (Pubitemid 34044602)
2. Baba K, Ishigami S, Arigami T, Uenosono Y, Okumura H, Matsumoto M, Kurahara H, Uchikado Y, Kita Y, Kijima Y, Kitazono M, Shinchi H, Ueno S, Natsugoe S (2011) Mesothelin expression correlates with prolonged patient survival in gastric cancer. J Surg Oncol 105: 195-199
3. Bharadwaj U, Li M, Chen C, Yao Q (2008) Mesothelin-induced pancreatic cancer cell proliferation involves alteration of cyclin E via activation of signal transducer and activator of transcription protein 3. Mol Cancer Res 6: 1755-1765
4. Bharadwaj U, Marin-Muller C, Li M, Chen C, Yao Q (2011a) Mesothelin confers pancreatic cancer cell resistance to TNF-alpha-induced apoptosis through Akt/PI3K/NF-kappaB activation and IL-6/Mcl-1 overexpression. Mol Cancer 10: 106
5. Bharadwaj U, Marin-Muller C, Li M, Chen C, Yao Q (2011b) Mesothelin overexpression promotes autocrine IL-6/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation. Carcinogenesis 32: 1013-1024
6. Chang K, Pastan I (1996) Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA 93: 136-140 (Pubitemid 26041483)
7. Chang K, Pastan I, Willingham MC (1992) Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer 50: 373-381
8. Chang MC, Chen CA, Hsieh CY, Lee CN, Su YN, Hu YH, Cheng WF (2009) Mesothelin inhibits paclitaxel-induced apoptosis through the PI3K pathway. Biochem J 424: 449-458
9. Cheng WF, Huang CY, Chang MC, Hu YH, Chiang YC, Chen YL, Hsieh CY, Chen CA (2009) High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma. Br J Cancer 100: 1144-1153
10. Einama T, Kamachi H, Nishihara H, Homma S, Kanno H, Takahashi K, Sasaki A, Tahara M, Okada K, Muraoka S, Kamiyama T, Matsuno Y, Ozaki M, Todo S (2011) Co-expression of mesothelin and CA125 correlates with unfavorable patient outcome in pancreatic ductal adenocarcinoma. Pancreas 40: 1276-1282
11. Hassan R, Bera T, Pastan I (2004) Mesothelin: a new target for immunotherapy. Clin Cancer Res 10: 3937-3942 (Pubitemid 38812466)
12. Hassan R, Broaddus VC, Wilson S, Liewehr DJ, Zhang J (2007a) Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts. Clin Cancer Res 13: 7166-7171 (Pubitemid 350276903)
13. Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham MC, Pastan I (2007b) Phase I study of SS1P, a recombinant antimesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 13: 5144-5149 (Pubitemid 47502082)
14. Hassan R, Ebel W, Routhier EL, Patel R, Kline JB, Zhang J, Chao Q, Jacob S, Turchin H, Gibbs L, Phillips MD, Mudali S, Iacobuzio-Donahue C, Jaffee EM, Moreno M, Pastan I, Sass PM, Nicolaides NC, Grasso L (2007c) Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun 7: 20
15. Hassan R, Ho M (2008) Mesothelin targeted cancer immunotherapy. Eur J Cancer 44: 46-53 (Pubitemid 350262830)
16. Hassan R, Kreitman RJ, Pastan I, Willingham MC (2005a) Localization of mesothelin in epithelial ovarian cancer. Appl Immunohistochem Mol Morphol 13: 243-247 (Pubitemid 41209017)
17. Hassan R, Laszik ZG, Lerner M, Raffeld M, Postier R, Brackett D (2005b) Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am J Clin Pathol 124: 838-845 (Pubitemid 41740183)
18. Hassan R, Schweizer C, Lu KF, Schuler B, Remaley AT, Weil SC, Pastan I (2010) Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: implications for cancer therapy. Lung Cancer 68: 455-459
19. Inami K, Abe M, Takeda K, Hagiwara Y, Maeda M, Segawa T, Suyama M, Watanabe S, Hino O (2009) Antitumor activity of anti-C-ERC/mesothelin monoclonal antibody in vivo. Cancer Sci 101: 969-974
20. Inami K, Kajino K, Abe M, Hagiwara Y, Maeda M, Suyama M, Watanabe S, Hino O (2008) Secretion of N-ERC/mesothelin and expression of C-ERC/mesothelin in human pancreatic ductal carcinoma. Oncol Rep 20: 1375-1380
21. Sobin LH, Wittekind CW (ed) (2002) TNM Classification of Malignant Tumors. Wiley-Liss: New York
22. Li M, Bharadwaj U, Zhang R, Zhang S, Mu H, Fisher WE, Brunicardi FC, Chen C, Yao Q (2008) Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer. Mol Cancer Ther 7: 286-296 (Pubitemid 351302523)
23. Ordonez NG (2003a) Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol 27: 1418-1428 (Pubitemid 37315193)
24. Ordonez NG (2003b) Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol 16: 192-197 (Pubitemid 36337423)
25. Swierczynski SL, Maitra A, Abraham SC, Iacobuzio-Donahue CA, Ashfaq R, Cameron JL, Schulick RD, Yeo CJ, Rahman A, Hinkle DA, Hruban RH, Argani P (2004) Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays. Hum Pathol 35: 357-366 (Pubitemid 38339611)
26. Yen MJ, Hsu CY, Mao TL, Wu TC, Roden R, Wang TL, Shih Ie M (2006) Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma. Clin Cancer Res 12: 827-831 (Pubitemid 43259864)